Hypothalamic-pituitary-adrenal axis suppression during inhaled or intranasal corticosteroid treatment

Advances in Therapy

Volumn 13, Issue 3, 1996, Pages 154-160

  Prenner, Bruce M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Allergy Associates Medical Group Inc   (United States)

Author keywords

beclomethasone dipropionate; budesonide; fluticasone propionate; hypothalamic pituitary adrenal (HPA) axis; inhaled corticosteroids; intranasal corticosteroids

Indexed keywords

BECLOMETASONE; BUDESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE;

ADRENAL FUNCTION; ADRENAL SUPPRESSION; ADULT; ALLERGIC RHINITIS; ARTICLE; ASTHMA; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DRUG SAFETY; FEEDBACK SYSTEM; FEMALE; HORMONAL REGULATION; HUMAN; HYPERADRENOCORTICISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MALE; MEDIATOR RELEASE; RISK ASSESSMENT;

EID: 0029946570     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Global Initiative for Asthma: Global Strategy for Asthma Management and Prevention. Bethesda, Md: National Heart, Lung, and Blood Institute; 1995. Publication no. 95-3659.
2. Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Am Rev Respir Dis. 1993;148:S1-S26.
3. Edfors-Lubs M-L. Allergy in 7000 twin pairs. Acta Allergol. 1971;26:249-285.
4. Newman U, Platts-Mills TAE, Phillips CD, Hazen KC, Gross CW. Chronic sinusitis: relationship of computed tomographic findings to allergy, asthma, and eosinophilia. JAMA. 1994;271:363-367.
5. Ratner P, Findlay S, Greenstein S, Nebesnak C. Beclomethasone dipropionate 84 mcg/spray in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol. 1993;91(1 pt 2):212.
6. Brannan MD, Herron JM, Reidenberg P, Affrime MB. Lack of hypothalamic-pituitary-adrenal axis suppression with once-daily or twice-daily beclomethasone dipropionate aqueous nasal spray administered to patients with allergic rhinitis. Clin Ther. 1995;17:637-647.
7. Knutsson U, Stierna P, Marcus C, Carlstedt-Duke J, Carlström K, Brönnegård M. Effects of intranasal glucocorticoids on endogenous glucocorticoid peripheral and central function. J Endocrinol. 1995;144:301-310.
8. Brown PH, Greening AP, Crompton GK. Large volume spacer devices and the influence of high dose beclomethasone dipropionate on hypothalamo-pituitary-adrenal axis function. Thorax. 1993;48:233-238.
9. Physicians' Desk Reference®. 50th ed. Montvale, NJ: Medical Economics Production; 1996.
10. Boe J, Bakke P, Rødølen T, Skorlund E, Gulsvik A. High-dose inhaled steroids in asthmatics: moderate efficacy gain and suppression of the hypothalamic-pituitary-adrenal (HPA) axis. Eur Respir J. 1994;7:2179-2184.
11. Grahnén A, Eckernäs S-Å, Brundin RM, Ling-Andersson A. An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br J Clin Pharmacol. 1994;38:521-525.
12. Allen & Hanburys. Flonase® (fluticasone propionate) nasal spray. Package insert, 1996.
13. Freigang B, Ashford DR. Adrenal cortical function after long-term beclomethasone aerosol therapy in early childhood. Ann Allergy. 1990;64:342-344.
14. Volovitz B, Amir J, Malik H, Kauschansky A, Varsano I. Growth and pituitary-adrenal function in children with severe asthma treated with inhaled budesonide. N Engl J Med. 1993;329:1703-1708.
15. Zwann DM, Odink RJH, Delemarre-Van De Waal HA, Dankert-Roelse JE. Acute adrenal insufficiency after discontinuation of inhaled corticosteroid therapy. Lancet. 1992;340:1289-1290.